From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
While B12 shots are primarily for those with deficiencies, some individuals (like athletes or those seeking an energy boost) choose them even without a diagnosed deficiency
[1] [2] This triple-receptor mechanism distinguishes it from currently approved agents such as semaglutide (a GLP-1 agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
By supporting red blood cell production and improving oxygen transport, these injections not only fight tiredness but also give your metabolism a helpful kickan advantage for weight loss efforts